



AJINOMOTO[®]

Corporate Press Release

7th January 2013

Ajinomoto Pharmaceuticals Have Obtained the Manufacturing and Marketing Authorisation for MOVIPREP[®], a New Oral Bowel Cleansing Agent in Japan

Ajinomoto Pharmaceuticals Co., Ltd. (President, Tomoyasu Toyoda; Headquarters, Tokyo, Japan; hereinafter “Ajinomoto Pharmaceuticals”) have obtained the authorisation in Japan for the manufacture and marketing of a new bowel cleansing agent MOVIPREP[®] (code: AJG522) which will be used for bowel preparation prior to colonoscopy and colon surgery.

This product was originally developed by Norgine B.V. (the Netherlands) and has been sold under the brand name of MOVIPREP[®] in Europe and North America and is the world’s most frequently administered branded bowel preparation prior to colonoscopy and other procedures requiring a clean bowel. Ajinomoto Pharmaceuticals have licensed the exclusive rights to develop, manufacture and sell the product in Japan.

Given the increased number of patients who suffer from colon cancer in Japan¹, the Japanese government have promoted cancer screening for the early detection of colon cancer based on the “Guidelines for intensive health education for cancer prevention and cancer screening (1998)” and “The 3rd 10-year comprehensive strategies against cancer (2003)” published by the Ministry of Health, Labour and Welfare. Ajinomoto Pharmaceuticals currently markets Niflec[®] which is used for cleaning the bowel prior to colonoscopy: Colonoscopy is currently the first recommendable examination in the 2nd stage

screening of colon cancer. Ajinomoto Pharmaceuticals expects that MOVIPREP[®], with its reduced volume of dosage will contribute to improving patients' quality of life.

Ajinomoto Pharmaceuticals is committed to a healthier and better quality of life of each individual patient through practice of "For Your Quality Of Life" to realize wishes of patients and medical practitioners.

ENDS

References

1 Hoi-Yan Yiu, Alice S. Whittemore, Atsuko Shibata et al. International Journal of Cancer, Volume 109, Issue 5, pages 777–781, 1 May 2004

<http://onlinelibrary.wiley.com/doi/10.1002/ijc.20030/full>

About Ajinomoto and Ajinomoto Pharmaceuticals

Ajinomoto is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Ajinomoto Pharmaceuticals, responsible for pharmaceutical business in Ajinomoto group, provides unique products, specializing in gastrointestinal diseases and metabolic diseases.

For more information: <http://www.ajinomoto-seiyaku.co.jp/en/index.html>

Media contact

Ajinomoto Pharmaceuticals Co., Ltd.

Corporate Planning Dept., Ajinomoto Pharmaceuticals Co., Ltd.

TEL: +81-(0)3-6280-9802

FAX: +81-(0)3-6280-9912

About Norgine

Norgine is a successful, independent European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2011, Norgine's net product sales were €246 million and the company employs over 1,000 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care.

The Company currently markets a range of products in various markets in its key therapeutic areas e.g. MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a bowel cleansing preparation, KLEAN-PREP[®] for large bowel preparation prior to colonoscopy or surgery, XIFAXAN^{®*} in the reduction of recurrence of episodes of overt hepatic encephalopathy and for the treatment of traveller's diarrhoea and ORAMORPH[®] for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France.

For more information: www.norgine.com.

Media Contact

Julie Hornby Winfield

Global Corporate Communications Manager

Phone: +44 1895 826600 or email to jhornbywinfield@norgine.com

* XIFAXAN is a registered trademark of Alfa Wasserman Hungary KFT, licensed to the Norgine group of companies. Product under licence from Alfa Wassermann. KLEAN PREP is a registered trademark of the Helsinn Healthcare group, licensed to the Norgine group of companies. ORAMORPH is a registered trademark of the Molteni Farmaceutici group, licensed to the Norgine group of companies.

PR2013Jan02.01.2013